Pharmaceutical Industry Today
Lysosomal Storage Diseases Market - North America expected the high growth rate by 2014 - 2020
Lysosomal storage diseases (LSDs) refer a group of genetic disorders that are caused by the deficiency of the lysosomal enzyme and activator proteins. Lysosomal enzyme helps in hydrolysis of protein, polysaccharide, DNA, RNA and lipid. In addition, lysosome also works as a waste disposal system of the cell by digesting unwanted material such as outside particles and unwanted macromolecules. Deficiency of lysosomal enzyme creates a defect in lysosomal functions, which results undigested material accumulation within the lysosome and causes disorders. Symptoms of lysosomal storage diseases are vary from person to person, it is depends on type of disorder, rate of progression, age of onset and others. Types of lysosomal diseases include gaucher disease, mucopolysaccharidosis, cystinosis, pompe disease and NPC. Some of the treatments for lysosomal storage diseases include enzyme replacement therapy, marrow replanting therapy and genetic therapy. On the basis of drug class global lysosomal storage diseases market can be segmented into ERTs, SRT and cystine-depletors.
Request Full TOC: http://www.persistencemarketresearch.com/toc/3145
North America, followed by Europe, has the largest market for lysosomal storage diseases due to increasing awareness and diagnosis of lysosomal storage diseases in this region. Asia is expected to show high growth rate in the lysosomal storage diseases market in next few years due to government initiatives and increasing awareness about rare diseases in the region.
Special provisions for rare and orphan diseases, technological advancement, increasing orphan disease research, new therapeutic approaches for genetic diseases and rise in government expenditure are expected to drive the market for global lysosomal storage diseases. In addition, rise in awareness about lysosomal storage diseases through government initiatives are expected to drive the market for lysosomal storage diseases. However, small patient population and huge cost involved in R&D of drug development is a restraining for the growth for global lysosomal storage diseases market.
Growing demographics and economies in the developing countries such as Japan is expected to offer new opportunities to lysosomal storage diseases market. In addition, innovations in rare diseases therapies and rise in awareness about the orphan diseases are expected to offer new opportunity to global lysosomal storage diseases market. However, increase in generic erosion is a challenge for the global lysosomal storage diseases market. Increasing number of partnerships and collaborations and rise in number of mergers and acquisitions in the market are some of the recent trends that have been observed in global lysosomal storage diseases market. Some of the major companies operating in the global lysosomal storage diseases market are Actelion Pharmaceuticals, Shire, Raptor, BioMarin Pharmaceutical, Genzyme Corporation, Recordati, Pfizer Inc., Sigma-Tau Pharmaceuticals, Inc., Mylan Inc. and Protalix Biotherapeutics.
Request Full Brochure of this report: http://www.persistencemarketresearch.com/samples/3145
Key points covered in the report
1) Report segments the market on the basis of types, application, products, technology, etc (as applicable)
2) The report covers geographic segmentation
North America
Europe
Asia
RoW
3) The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020
4) The report provides company profiles of some of the leading companies operating in the market
5) The report also provides porters five forces analysis of the market.-
About Us
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Contact
Addie Thomas
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!